Showing results (21-30 of 30) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 30 results.
Clinical and Translational Gastroenterology|July 30, 2025
Actual and perceived risk of colorectal neoplasia in first-degree relatives of colorectal cancer patientsJulia Hibbert, Korbinian Weigl, Kaja Tikk, et al.
Frontiers in Oncology|January 1, 2026
What can claims data tell us about risk factors and survival of patients with hepatocellular carcinoma? Insights from a German population-based studySelina Becht, Najib Ben Khaled, Simone Schrodi, et al.
International Journal of Cancer|January 27, 2017
Methylated free-circulating HPP1 DNA is an early response marker in patients with metastatic colorectal cancerAndreas Herbst, Nikolay Vdovin, Sanja Gacesa, et al.
European Journal of Cancer (Oxford, England : 1990)|September 6, 2023
Changing treatment landscape associated with improved survival in advanced hepatocellular carcinoma: a nationwide, population-based studyNajib Ben Khaled, Bernhard Mörtl, Dominik Beier, et al.
Therapeutic Advances in Medical Oncology|October 27, 2025
Treatment gaps and survival outcomes of hepatocellular carcinoma: insights from a nationwide, claims-based studySimone Schrodi, Karin Berger-Thürmel, Selina Becht, et al.
European Radiology|June 10, 2026
Histopathological outcomes of CT-guided high-dose-rate interstitial brachytherapy for HCC and predictive accuracy of the LI-RADS Radiation Treatment Response Algorithm v2024Elif Öcal, Osman Öcal, Stefanie Corradini, et al.
European Journal of Nuclear Medicine and Molecular Imaging|August 2, 2022
Addition of Y-90 radioembolization increases tumor response and local disease control in hepatocellular carcinoma patients receiving sorafenibOsman Öcal, Kerstin Schütte, Christoph J Zech, et al.
JHEP Reports : Innovation in Hepatology|February 4, 2026
Early mortality in atezolizumab/bevacizumab for HCC is associated with impaired liver function and alterations of systemic immunityIgnazio Piseddu, Leonie S Jochheim, Katrin Boettcher, et al.
Therapeutic Advances in Medical Oncology|February 24, 2026
Sequential or upfront triple combination with durvalumab, tremelimumab, and bevacizumab for patients with unresectable hepatocellular carcinoma: the MONTBLANC trial protocol (AIO-HEP-0325/ass)Najib Ben Khaled, Ursula Ehmer, Ilja Kubisch, et al.
Hepatology (Baltimore, Md.)|December 7, 2024
Outcome and management of patients with hepatocellular carcinoma who achieved a complete response to immunotherapy-based systemic therapyBernhard Scheiner, Beodeul Kang, Lorenz Balcar, et al.
Pageof 3